Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 3/20 | 0.37 |
| ▸ | GNAO1 | P09471 | 3/20 | 0.37 |
| ▸ | GNAI1 | P63096 | 3/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 9/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 9/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 9/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 9/20 | 0.35 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.35 |
| ▸ | RAD52 | P43351 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24672102 | 1.00 | GNAI3 (0.37) | GNAI3GNAO1GNAI1CHRNB2CHRNB4 | |
| SCHEMBL21581542 | 1.00 | GNAI3 (0.37) | GNAI3GNAO1GNAI1CHRNB2CHRNB4 | |
| SCHEMBL20758573 | 1.00 | GNAI3 (0.37) | GNAI3GNAO1GNAI1CHRNB2CHRNB4 | |
| SCHEMBL29869645 | 1.00 | GNAI3 (0.37) | GNAI3GNAO1GNAI1CHRNB2CHRNB4 | |
| SCHEMBL10259483 | 1.00 | GNAI3 (0.37) | GNAI3GNAO1GNAI1CHRNB2CHRNB4 | |
| Ammonia Solution, Strong SCHEMBL23644743 | 0.98 | GNAI3 (0.36) | GNAI3GNAO1GNAI1CHRNB2CHRNB4 | |
| Hydrochloric Acid SCHEMBL21580889 | 0.98 | GNAI3 (0.40) | GNAI3GNAO1GNAI1CHRNB2CHRNB4 | |
| Hydrochloric Acid SCHEMBL23700609 | 0.98 | GNAI3 (0.40) | GNAI3GNAO1GNAI1CHRNB2CHRNB4 | |
| Hydrochloric Acid SCHEMBL23700611 | 0.98 | GNAI3 (0.40) | GNAI3GNAO1GNAI1CHRNB2CHRNB4 | |
| SCHEMBL11968900 | 0.89 | GNAI3 (0.36) | GNAI3GNAO1GNAI1CHRNB2CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210238197-A1 | NOVEL OXOQUINOLIZINE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2021-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238197-A1 | NOVEL OXOQUINOLIZINE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION | O60361, ARG1, QDPR | GNAI3 1018/4885GNAO1 761/4885GNAI1 459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.